Aug. 17 at 10:58 AM
Mizuho⬆️its Top Pick
$AMLX's PT to
$30, stayed Outperform and said -- Post-the company's 2Q results, we now raise our AMLX PT to
$30, a 25% increase vs. our prior
$24.
$MBX $VOGX RICFY ZLDPF ZLDPY
Mizuho added—This reflects updated (i.e., higher) launch pricing assumptions (details within) for lead asset avexitide, a first-in-class GLP-1 receptor antagonist for which top-line P3 LUCIDITY study data in the setting of post-bariatric hypoglycemia/PBH (an orphan indication) are now expected in late August/early September (a refinement vs. a previously guided 3Q26 timeline).
As for the stock, heading into the P3 data, YTD performance has impressed, with AMLX shares now +79% (vs. +29% XBI); that said, in light of our new PT (which implies 39% upside potential), we see scope for further upside on a positive P3 data outcome estimating a potential incremental
$10-15 move higher from current levels.
As such, and given our confidence ahead of data, we stay OP-rated on AMLX, a top 2026 pick.
